Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen
Executive Summary
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
You may also be interested in...
Ocuphire Posts Second Phase III Success In Reversing Pupil Dilation
Nyxol is almost set for an NDA filing for reversal of dilation during eye exams/surgery. The reformulation of phentolamine is also being studied in presbyopia, setting up possible competition with AbbVie’s Vuity.
Bouncing Back From A Phase III Flop
The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.
Zydus Cadila First Off The Block In NASH After India Approval
Cadila Healthcare has received the first approval globally, in India, for a NASH therapy, after the national regulator cleared its candidate saroglitazar. The company also expects to begin Phase III trials in the US in the second quarter of fiscal 2021.